NXTCNextCureNXTC info
$1.40info1.45%24h
Global rank26619
Market cap$39.06M
Change 7d-
YTD Performance20.69%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    NextCure (NXTC) Stock Overview

    NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

    NXTC Stock Information

    Symbol
    NXTC
    Address
    9000 Virginia Manor RoadBeltsville, MD 20705United States
    Founded
    -
    Trading hours
    9:30 AM - 4:00 PM ET
    Website
    https://www.nextcure.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    240 399 4900

    NextCure (NXTC) Price Chart

    -
    Value:-

    NextCure Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.40
    N/A
    Market Cap
    $39.06M
    N/A
    Shares Outstanding
    27.90M
    N/A
    Employees
    99.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org